Resistance Transition of <i>Pseudomonas aeruginosa</i> in SARS-CoV-2-Uninfected Hospitalized Patients in the Pandemic.

aeruginosa in uninfected patients, which ranked third (14.35% among 913 bacterial isolates) in the pre-pandemic year, was the leading pathogen among the 829 bacterial isolates (22.31%) in the post-pandemic year, consistent with a previous study, in that study, an increasing trend of P. aeruginosa isolates was observed. 7 The pandemic has been reported to influence the use of antimicrobials and antimicrobial resistance in COVID patients co-infected with P. aeruginosa . 14 In this study, the resistant rates of P. aeruginosa significantly increased to ceftazidime, ciprofloxacin, and gentamicin, in contrast, resistant rates decreased significantly to piperacillin/tazobactam and imipenem.

also in 63,971 other papers